Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Etoposide phosphate, the water soluble prodrug of etoposide.

Literature DB >> 8933576

Etoposide phosphate, the water soluble prodrug of etoposide.

Abstract

Etoposide (Vepesid) is a widely used drug in a variety of neoplasms. To improve the pharmaceutical characteristics of etoposide, etoposide phosphate (Etopophos, Bristol-Myers Squibb) has been developed as a prodrug. Etoposide phosphate is the phosphate ester derivative of etoposide. In comparison to the parent compound, etoposide phosphate is highly soluble in water and can be readily formulated for intravenous use, resulting in higher clinical application. This paper presents information on the pharmaceutical properties and the current status of etoposide phosphate in clinical trials.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1996 PMID： 8933576 DOI： 10.1007/bf00820727

Source DB: PubMed Journal: Pharm World Sci ISSN： 0928-1231

31 in total

Review 1. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors: J M Henwood; R N Brogden
Journal: Drugs Date: 1990-03 Impact factor: 9.546

Review 2. The human alkaline phosphatases: what we know and what we don't know.

Authors: H Harris
Journal: Clin Chim Acta Date: 1990-01-15 Impact factor: 3.786

3. Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.

Authors: J H Beijnen; A U Beijnen-Bandhoe; A C Dubbelman; R van Gijn; W J Underberg
Journal: J Parenter Sci Technol Date: 1991 Mar-Apr

4. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

Authors: M L Slevin; P I Clark; S P Joel; S Malik; R J Osborne; W M Gregory; D G Lowe; R H Reznek; P F Wrigley
Journal: J Clin Oncol Date: 1989-09 Impact factor: 44.544

5. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.

Authors: S Kaul; L N Igwemezie; D J Stewart; S Z Fields; M Kosty; N Levithan; R Bukowski; D Gandara; G Goss; P O'Dwyer
Journal: J Clin Oncol Date: 1995-11 Impact factor: 44.544

6. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer.

Authors: J D Hainsworth; N Levitan; G L Wampler; C P Belani; M S Seyedsadr; J Randolph; L P Schacter; F A Greco
Journal: J Clin Oncol Date: 1995-06 Impact factor: 44.544

7. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.

Authors: P I Clark; M L Slevin; S P Joel; R J Osborne; D I Talbot; P W Johnson; R Reznek; T Masud; W Gregory; P F Wrigley
Journal: J Clin Oncol Date: 1994-07 Impact factor: 44.544

Etoposide phosphate, the water soluble prodrug of etoposide.

Review 1. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Review 2. The human alkaline phosphatases: what we know and what we don't know.

3. Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.

4. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

5. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.

6. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer.

7. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.

8. The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.

9. Phase I clinical and pharmacokinetic study of oral etoposide phosphate.

10. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

Review 1. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

2. Theranostic etoposide phosphate/indium nanoparticles for cancer therapy and imaging.

Review 3. Topoisomerases as anticancer targets.

4. Editorial for Cancer Virtual Issue.